Literature DB >> 20378755

Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.

Vanesa Caruso1, Augusto Di Castelnuovo, Susana Meschengieser, Maria A Lazzari, Giovanni de Gaetano, Sergio Storti, Licia Iacoviello, Maria Benedetta Donati.   

Abstract

Thrombotic complications in hematologic malignancies have important clinical implications. In this meta-analysis we sought to obtain accurate estimates of the thrombotic risk in lymphoma patients. Articles were searched in electronic databases and references. Eighteen articles were identified (29 cohorts, 18 018 patients and 1149 events). Pooled incidence rates (IRs) were calculated by the use of a method based on the exact maximum likelihood binomial distribution. The global IR of thrombosis was 6.4% (95% confidence interval [CI] 6.0%-6.8%). The global IRs of venous or arterial events were 5.3% (95% CI, 5.0%-5.7%) and 1.1% (95% CI, 0.9%-1.2%), respectively. The IR of thrombosis observed in subjects with non-Hodgkin lymphoma (NHL) was 6.5% (95% CI, 6.1%-6.9%), significantly greater than that observed for patients with Hodgkin lymphoma (4.7%; 95% CI, 3.9%-5.6%). Within NHL, patients with high-grade disease had a greater risk of events (IR 8.3%; 95% CI, 7.0%-9.9%) than low-grade disease (IR 6.3%; 95% CI, 4.5%-8.9%). This meta-analysis shows that the IR of thrombosis in lymphoma patients is quite high, especially in those with NHL at an advanced stage of the disease. These results may help better defining lymphoma populations at high thrombotic risk, to whom prophylactic approaches could be preferentially applied.

Entities:  

Mesh:

Year:  2010        PMID: 20378755     DOI: 10.1182/blood-2010-01-258624

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Cardiovascular endocrinology: Risk of venous thromboembolism with glucocorticoids.

Authors:  John A Heit
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

2.  Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.

Authors:  Radhika Gangaraju; Yanjun Chen; Lindsey Hageman; Jessica Wu; Liton Francisco; Michelle Kung; Emily Ness; Mariel Parman; Daniel J Weisdorf; Stephen J Forman; Mukta Arora; Saro H Armenian; Smita Bhatia
Journal:  Cancer       Date:  2019-08-30       Impact factor: 6.860

3.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Authors:  Ajay K Gopal; Stefano R Tarantolo; Naresh Bellam; Damian J Green; Melissa Griffin; Tatyana Feldman; Anthony R Mato; Amy J Eisenfeld; Scott C Stromatt; Andre Goy
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

4.  Images in Vascular Medicine: Distal radial and ulnar artery thrombosis in a cancer patient with a history of chronic handgun use.

Authors:  Anthony N Hage; Jonathan L Eliason; Yogendra Kanthi
Journal:  Vasc Med       Date:  2017-11-22       Impact factor: 3.239

5.  Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation.

Authors:  Ang Li; Chris Davis; Qian Wu; Shan Li; Madeline F Kesten; Leona A Holmberg; Ajay K Gopal; David A Garcia
Journal:  Blood Adv       Date:  2017-04-27

Review 6.  Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.

Authors:  Franco Dammacco; Angelo Vacca; Pasquale Procaccio; Roberto Ria; Ilaria Marech; Vito Racanelli
Journal:  Clin Exp Med       Date:  2013-03-02       Impact factor: 3.984

7.  Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.

Authors:  Paolo Strati; Preetesh Jain; Ralph J Johnson; Sheryl Forbes; Lei Feng; Felipe Samaniego; Maria A Rodriguez; Luis E Fayad; Fredrick Hagemeister; Jason Westin; Michael Wang; Sattva S Neelapu; Loretta J Nastoupil; Nathan H Fowler
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113

8.  Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma.

Authors:  Anna L Parks; Swetha Kambhampati; Bita Fakhri; Charalambos Andreadis; Lissa Gray; Sandy W Wong; Nina Shah; Margaret C Fang
Journal:  Leuk Lymphoma       Date:  2020-12-01

9.  Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma.

Authors:  Miyabi Saito; Nolan A Wages; David Schiff
Journal:  J Neurooncol       Date:  2021-06-23       Impact factor: 4.130

10.  The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients.

Authors:  Hikmat Abdel-Razeq; Mohammad Ma'koseh; Rashid Abdel-Razeq; Rula Amarin; Alaa Abufara; Razan Mansour; Mohammad Manasrah; Mohammad Al-Rwashdeh; Rayan Bater
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.